Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse

CASTLE BIOSCIENCES INC

2025-Q1 EPS reported -$0.90 revenue$87,988,000

Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.
Net loss $(0.90) per share incl. $20.1M amortization acceleration; adjusted net loss $(0.20); Adj. EBITDA $13.0M.
FY 2025 revenue guidance raised to $287-297M from prior $280-295M.
Signed definitive agreement to acquire Previse, a GI health company focused on esophageal cancer; no terms disclosed.
DecisionDx-Melanoma surpassed 200,000 test orders; IDgenetix test to be discontinued effective May 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.